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ABSTRACT
Breast cancer is the second largest cause of cancer-related deaths in women all over
the world. Epidemiological studies suggest that the consumption of high-fat diets can
promote the incidence of breast cancers in both developed and developing countries. In
particular, the lipid-rich diet contains arachidonic acid (AA, a C20:4 polyunsaturated fatty
acid), which has been shown to be associated with tumor formation in breast tissues.
Nevertheless, the actual mechanism by which AA induces the metastatic transformation
and malignancy is not well understood. The goal of my dissertation, therefore, is to
identify the molecules and unravel the pathways that participate in AA-induced
carcinogenesis. In this investigation, two different breast cancer cells were used—MDAMB-231 and MCF7. Although both cells were derived from the cancerous tissues of the
human breast, they display different phenotypes. For example, the estrogen-receptornegative MDA-MB-231 cells are highly invasive, with typical fibroblast structures,
whereas MCF7 cells are estrogen receptor positive and are weakly invasive, luminal
epithelial cells. Briefly, both MDA-MB-231 and MCF7 cells were treated with AA (100
M) and a lipoxygenase inhibitor (nordihydroguaiarectin acid or NDGA, 10 M),
followed by the isolation and characterization of the AA metabolites (i.e., eicosanoid
molecules) by high-performance liquid chromatography (HPLC). Immunoblot and
confocal microscopy were performed to elucidate the protein expression and
intracellular targeting of 5-lipoxygenase (5-LOX), the enzyme that utilizes AA to
synthesize LTB4 and other leukotrienes (LTs). Metastatic migration was analyzed by
wound-healing and matrigel-mediated invasion assays. The involvement of lipid rafts
(LRs) in inducing migration/invasion of MDA-MB-231 cells was evaluated by treating the
vi

cells with an LR disruptor, methyl-cyclodextrin (MBCD). The analysis of LR
components (i.e., caveolin-1, flotilin and cholesterol) was also monitored.
The results suggest that while MDA-MB-231 cells produced high levels of
prostaglandins

(i.e.,

PGE2

and

PGD2),

MCF7

cells

synthesized

excess

hydroxyeicosatetraenoic acid (HETEs) compounds. Interestingly, MDA-MB-231 cells
when stimulated with AA showed increased synthesis of LTB 4 (~4-fold) and decreased
the production of PGE2 and PGD2 (~2-fold). In contrast, AA suppressed the synthesis of
PGE2, PGD2, LTB4, and HETE compounds in MCF7 cells, suggesting that AA affects
the eicosanoid synthesis in MDA-MB-231 and MCF7 cells differently. Furthermore, I
found that the AA treatment stimulated the expression of 5-LOX and promoted the
migration and invasion by MDA-MB-231 cells. Interestingly, NDGA significantly blocked
the AA-induced 5-LOX activation and cellular migration/invasion. AA also increased the
phosphorylation of NF and produced excess IL-6 and IL-8. Again, AA showed
minimal or no effects on 5-LOX, cytokines, and NF activation in MCF7 cells, which
suggests that AA activates the different sets of molecules/pathways in non-invasive and
invasive breast cancer cells, respectively. Because AA stimulated the synthesis of LTB 4
in MDA-MB-231 cells, I propose that the autocrine and paracrine signaling caused by
LTB4 activates NF-mediated cytokine release, which promotes cellular inflammation
and malignancy in invasive breast cancers. The results with MBCD that blocked the
invasion and migration of MDA-MB-231 cells, along with the increased synthesis of
caveolin-1 and flotilin under the influence of AA, further supports the idea that the
involvement of LRs is essential in AA-mediated migration and invasion of MDA-MB-231
breast cancer cells.
vii

Finally, my results point out that the LTB4, which is synthesized by AA, activates the
inflammatory pathways that are critical for causing the metastatic invasion of breast
cancer cells. In my opinion, this is a novel finding in the field of breast cancer, and it is
likely that 5-LOX pathway could be an ideal target for developing new chemotherapies
to treat the patients with metastatic breast cancers.
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CHAPTER 1

GENERAL INTRODUCTION
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1.1. FREQUENCY, DISTRIBUTION AND EPIDEMIOLOGY OF BREAST CANCER

Breast cancer is widespread among women across the globe. A recent estimate
suggests that cancer in breast tissues comprises approximately 20% of all cancers in
women [1]. Worldwide, more than 1.1 million cases are diagnosed each year, and
approximately 410,000 cases result in death [2]. Figure 1 shows the incidence rate and
mortality rate (per 100,000 populations) of breast cancer globally as reported by the
International Agency for Cancer Research in France (www.iarc.fr). However, the
incidence and mortality rates are higher in the U.S., Canada, Brazil, Australia, and
Europe. In 2011, 200,000 new cases of breast cancer were reported in the U.S., and
the number of deaths reached almost 39,000 [Table-1, American Cancer Society].
Interestingly, recent advancements in diagnosis and treatment have resulted in
approximately 2 million breast cancer survivors in the United States [3].Most of the
commonly diagnosed breast cancers are non-invasive and estrogen-receptor (ER)
positive and these are responsive to hormone and chemotherapy [4]. On the other
hand, the invasive breast cancers are ER negative but progesterone receptor (PR) and
human epidermal growth factor receptor-2 (HER-2) positive. Still, there are growing
reports of increased incidence of double-negative breast cancer (ER positive, PR and
HER-2 negative) and triple-negative breast cancer (ER, PR, and HER-2 negative) in the
U.S. [5; 6]. These receptor-negative breast cancers are highly invasive and metastatic
and are usually non-responsive to hormone and common chemotherapies. During
metastasis, breast cancer cells migrate quickly, and this migration allows the cells to
spread within the healthy tissues, distant organs, or even to the bone marrow.

2

Incidence of breast cancer worldwide
A

Mortality from breast cancer worldwide
B

Figure 1
Breast cancer around the world
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Figure 1. Breast cancer around the world
Age standardized incidence rate (Figure 1A) and age standardized mortality rate
(Fig.1B) in a global perspective is shown in this figure. The incidence and mortality rates
are calculated in per 100,000 people. Source: GLOBOCAN, France.
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The mechanisms of cell migration and invasion involve complex interactions among
various proteins and signaling molecules, activation of focal-adhesion kinase, actin
polymerization, lammellopodia formation, and the involvement of extracellular matrix as
well as integrin molecules [7].
Reports suggest that various environmental factors, carcinogens, hormones, and fatty
acids such as arachidonic acid (AA, C20:4) can influence the migration of various cells,
including those of breast cancer [8; 9]. A recent study on breast cancer epidemiology by
Kwan et al. [10] suggested that frequent alcohol consumption may enhance the risk of
breast cancer recurrence in post-menopausal and obese women. Another recent multiethnic cohort study by Chen et al. [11] reported that there is no evidence for the
association between obesity risk variants and breast cancer risks among women across
ethnic groups. Conroy et al. [12] showed that in multi-ethnic populations women with
higher breast density may have an increased risk for ER+PR+ but not ER-PR- tumors.
Breast cancer is the most commonly diagnosed cancer in white females, whereas
Hispanic women have the maximum incidence rate of non-treatable, triple-negative
breast cancer (TNBC). The consumption of red meats, high-fat diets, and smoking are
common in the U.S.-Mexico border region. It is also known that in comparison with the
general population, the Hispanic community in the U.S.-Mexico border area is medically
underserved and more vulnerable to various forms of cancers. The lifestyle may play an
important role in the disease progression in this ethnic population.

5

Table-1
Estimated new breast cancer cases and deaths by age, US,
2011. Table-1 demonstrates the total number of in situ and
invasive breast cancer incidences and number of deaths by
age in the United States of America in 2011 (Source:
American cancer Society).
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1.2. MAMMALIAN PHYSIOLOGY, HORMONAL REGULATION, TUMOR IMMUNOLOGY AND
GENETICS

Clinically, breast cancers are identified and characterized based on their origin in the
mammary tissue. The two major types of breast cancers are lobular and ductal. Figure 2
compares the normal breast with a cancerous breast. With the development of the
cancerous process, the lobules are distorted, and the skin abrasion becomes evident.
The lobular carcinoma develops in the milk-producing glands or lobules of the breast
tissue, whereas the presence of cancer cells in the milk ducts produces ductal
carcinoma. While lobular carcinomas are the ones that are mostly invasive, ductal
cancers are mostly non-invasive and non-life-threatening. The spread of cancerous
tissue to the lymph nodes is common in the invasive cancers, which results in the
formation of swollen lymph nodes in the auxiliary region, whereas the circulatory tumor
cells (CTC) can be distributed to different organs by the blood stream when the cancer
cells migrate to the blood vessels present in the breast.
For diagnostic and therapeutic purposes, breast cancers are also classified according to
the over-expression of the hormonal receptors or by genetic mutations. Estrogen and
progesterone are the two important hormones that play a significant role in maintaining
the physiological homeostasis in women. Therefore, the unregulated synthesis of these
hormones and the malfunctioning of their receptors can lead to pathological conditions
that result in the up- or down-regulation of many signal-producing molecules, which in
turn causes abnormal cell proliferation in the breast tissue (Figures 3A and 3B).
Estrogen receptors (ER) and progesterone receptors (PR) play a key role in generating
the signals upon binding to estrogen and progesterone hormones.
7

a

b

Figure 2
Breast Physiology
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Breast profile:
A Ducts
B Lobules
C Dilated section of duct
to hold milk
D Nipple
E Fat
F Pectoralis major muscle
G Chest wall/rib cage
Enlargement
A Normal duct cells
B Basement membrane
C Lumen (center of duct)

Figure 2. Breast physiology

Figure 2A is a diagram of a normal breast comprising of ducts, lobules, nipple, muscle,
etc. The duct cells and lumen are shown in an enlarged image. Figure 2B demonstrates
the cancerous breast tissue, where lobules are distorted and skin is abrogated.
(www.breastcancer.org)
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A

B

Figure 3
Estrogen signaling pathway
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Fig.3. Estrogen signaling pathway
Figure 3A represents the binding of estrogen to estrogen receptor (ER). ER is localized
in the nuclear membrane and acts through a G-protein-coupled estrogen receptor,
GPR30. Figure 3B shows the synthesis of estradiol (E2) by aromatase gene that leads
to the activation of estrogen receptor (ER) and cell proliferation during the breast
cancer. ER activation is also linked to the activation of epidermal growth factor receptor
(EGFR) that stimulates the cycloxygenase (COX-2) and subsequent prostaglandin E2
(PGE2) production. Ref: Figure 3A.The Weatherman Lab, Rose Hulman Institute of
Technology; Figure 3B. [13].
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ER has two different subunits, located in nuclear membrane—i.ealpha and beta
(—and the ratio between these two receptor subunits is important for maintaining the
hormonal homeostasis. GPR30, a G-protein coupled receptor also binds to estrogen or
estrogen antagonist [14] and this ligand-receptor interaction is important for promoting
the aggressive nature of breast tumors. Reports indicate that GPR30 expression is
linked to the generation of tamoxifen resistance breast cancer cells [15]. Pandey et al.
found that the interaction between connective tissue growth factor and GPR30 is
essential for the metastatic migration of breast cancer cells [14].
The other major receptors such as human epidermal receptor-2 (HER2) and epidermal
growth factor receptor (EGFR) are over-expressed in a large number of breast cancer
patients. Different growth factors, including chemokines or eicosanoids, may bind to
these receptors, and they can activate different signal-transduction molecules and
promote cell proliferation, angiogenesis, invasion, and metastasis.
Breast cancer can also be categorized according to the distribution of elevated levels of
hormonal receptor proteins. ER+, PR+, or HER+ cancers are characterized according to
the enhanced level of receptor proteins in the breast tissue. Immuno-histochemistry
(IHC) and PCR analyses of a patient’s samples are dependable diagnostic tools to
diagnose the type of breast cancer, and accordingly the patient receives medications. If
the pathological test is unable to identify any such receptor up-regulation, then the
cancer is considered a triple-negative cancer, which has poor prognosis. In addition to
the ER and PR, HER 2 and epidermal growth-factor receptors (EGFR) are critical for
growth and malignancy. These receptors are able to bind to various ligands and can
activate signaling molecules, which subsequently up-regulate the signaling of several
12

kinases and the transcription of various oncogenes, as well as suppressing the activities
of tumor suppressor genes. ER, PR, HER, and EGFR are the most studied and
diagnosed receptors in breast cancer patients.

Oncogenes are the mutated form of normal cellular genes, and the activation of
oncogenes could be responsible for transforming normal cells into malignancy. The
oncogenes, such as c-myc [16], HER-2 [17] and EGFR [18] were found to be
associated with the incidence of breast cancer. There is another group of genes called
tumor-suppressor genes that can function as negative regulators of the growth,
invasion, and metastasis of cells [19]. These tumor-suppressor genes are vital for
maintaining DNA repair, genomic stability, transcriptional regulation, and cell-cycle
control [20]. The inactivation or mutation of tumor-suppressor genes is important in the
development and progression of breast cancer. Some of the important tumorsuppressor genes associated with breast cancer are p53, PTEN, the retinoblastoma
gene (Rb), TP53, CDH1, BRCA1, BRCA2 and BRCA3 [21; 22; 23; 24]. The BRCA1
protein interacts with other proteins such as RAD51 and BARD1 to maintain the stability
of DNA. BRCA1 and BRCA2 mutations (Figure 4) are inherited in an autosomal
dominant manner, and both males and females have a 50% risk of passing the mutation
on to children of both sexes. The mutations in the BRCA genes are associated with 5–
10% of breast cancer cases. The risk of developing breast cancer in individuals with a
BRCA1 mutation may be as high as 85% [American Cancer Society]. Other than
maintaining the repair mechanism, BRCA1 is also involved in embryonic development.
Although mutation in the BRCA1 gene is mostly associated with breast cancer
incidence, but it has also been found to be associated with fallopian tube cancer,
13

pancreatic cancer and male breast cancers. In breast cancer patients, more than 1,000
mutations have been detected to be associated with the BRCA1 gene, and patients who
carry these kinds of mutations are more prone to develop metastasis. It is interesting
that bilateral oophorectomy has been shown to have a reduced breast cancer risk in
patients with BRCA1 mutation due to a reduced level of ovarian hormone availability in
the system [23].
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A

B

Figure 4
Breast cancer genetics
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Figure 4. Breast cancer genetics
Fig.4A shows the domains of breast cancer type 1 (BRCA1) and breast cancer type 2
(BRCA2) genes. The different domains are Zn binding RING (really interesting new
gene) finger domain near amino terminus; NLS, nuclear localization signal; p53 and
RAD51 binding site. BRCA2 (Fig.4B) interacts with BRCA1 through a specific domain.
Point mutations in RING and BRCA1 carboxy terminus domain have been found in early
onset breast cancers. Serines phosphorylated by oncogene ATM in response to DNA
damage [25].
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Among the X-chromosome genes, tissue inhibitor of metalloproteinases-1(TIMP-1) is
up-regulated in breast cancer [26]. TIMP-1 has been recently proposed as a potential
biomarker for breast cancer [27].
It has been observed that tissue homeostasis is severely disturbed in breast cancer and
that it is infiltrated by macrophages as well as by mast cells, which secrete cytokines,
chemokines, growth factors, and matrix proteases [28]. The tumor micro-environments
are filled up with immune mediators and produce chronic inflammation. The immune
profiles of breast tumor patients are distinct from those of healthy individuals on the
basis of tumor micro-environment and extra-cellular matrix. A recent study by Xu et al.
[29] found a significant increase of CD27 and CD70 (two major co-stimulatory
molecules regulating the expansion and differentiation of T-cell function) in a
subpopulation of patients affected with ER+/PR+ breast cancer in China. The tumor cells
escape from the immune surveillance mechanisms due to the chronic pro-tumorigenic
inflammation. The T cells become dysfunctional or less active in malignancy, and the
regulatory T cells are found in the lymphoid organs and neoplastic tissues. Bower et al.
[30] reported a significant increase in CD4+ T cells in breast cancer survivors, whereas
B cells, natural killer cells, granulocytes, and monocytes were not altered. Several trials
to develop a vaccine against breast cancer are in progress, and recently Wang et al.
[31] showed a better efficacy of DEC-HER2 fusion monoclonal antibody in a mouse
model to induce a high level of broad and multifunctional CD4+ T-cell immunity, CD8+
T-cell responses, and humoral immunity specific for HER2 antigen.
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1.3. Lipids, Lipid Rafts and Cell Signaling in Breast Cancer

Dietary fats have been known to play a critical role in the etiology of cancer.
Epidemiological studies carried out over the years have documented that diets high in
animal fat and omega-6 polyunsaturated fatty acid ( PUFA) contribute to an
increased risk of breast cancer [32; 33]. Dietary PUFA has a profound influence on the
growth rate of transplantable human breast cancers in immunodeficient mouse [34]. It
has also been shown that diets containing omega-3 polyunsaturated fatty acids (-3
PUFA) suppress the tumorigenesis in mouse [35]. Although dietary fatty acids and lipids
have been implicated in causing cancer, the mechanisms by which they initiate this
disease are not completely understood. Recent studies indicate that a high intake of
dietary fat results in increased production of bile acid along with different eicosanoid
molecules such as prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs),
hydroxyeicosatetraenoic acids (HETE) compounds, and others. Figure 5 depicts a
general scheme of AA metabolism. Eicosanoids have a regulatory effect on cell growth
in cancer as well as in non-cancer cells [36; 37; 38; 39]. These compounds enhance the
proliferative activity of epithelial cells by increasing ornithine decarboxylase that is
involved in cell division [40].
The synthesis of various signaling molecules like protein kinase C, NF, MAPK,
mTOR, ERK1/2, PI3K/Akt (Figures 6 and 7) play important roles in the activation of
different oncogenes in invasive breast cancers that promote angiogenesis, invasion,
and migration.

18

Figure 5
Arachidonic acid signaling/metabolism
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Figure 5. Arachidonic acid signaling/metabolism
Arachidonic acid (AA), present in the lipid rich diet, and incorporated into membrane
phospholipids, forming arachidonoyl-phospholipid complex. This complex is hydrolyzed
by cytoplasmic phospholipase A2 (cPLA2) and releases free and unesterified AA. Free
AA under influence of cycloxygenase (COX) and lipoxygenase (LOX) produces different
inflammatory molecules like prostaglandins (PGG2, PGH2, PGI2, PGE2 and PGD2),
thromboxanes (TXA2), leukotrienes (12-HETE, 15-HETE, LTA4, LTB4, LTC4 and LTD4).
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Table-2
Important eicosanoids and their functions. The physiological and pathological
effects generated by different eicosanoids are listed in.
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A

B

Figure 6.
PI3K, mTOR, Akt and MAPK pathway in cancer
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Figure 6: PI3K, mTOR, Akt and MAPK pathway in cancer. Figure 6A demonstrates
the activation of phosphoinositide-3-kinase (PI3K)/Akt pathway by ligand binding with a
tyrosine receptor kinase. Phosphotase and tensin homolog (PTEN) is a tumor
suppressor gene which can block this activation. Akt activation causes the stimulation of
mammalian target of rapamycin (mTOR), which is responsible for activation of several
oncogenes. Everolimus is an anti-cancer drug which inhibits mTOR. [41].
Figure 6B depicts the Ras/Raf/MEK/MAPK pathway. External growth factor and/or
stress response elements may activate the membrane bound receptor tyrosine kinase
which subsequently activates Ras/Raf/MEK/MAPK activation through a series of
phosphorylation. MAPK activation stimulates the expression of several genes which are
associated with cell proliferation and cancerous signaling [42].
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Many new therapeutic approaches are being targeted against these signaling molecules
for the prevention of angiogenesis and metastasis. The target genes associated with
promoting cancerous events are, C-JUN, ATF-2, SP-1, c-MYC, CREB, c-FOS, STAT,
ELK, etc.
The primary mechanism for endogenous fatty-acid syntheses is carried out by an
enzyme called fatty-acid synthase (FAS), which is up-regulated during tumor formation
and metastasis [43; 44]. It has also been suggested that omega-6 fatty acids (i.e., AA
and linoleic acid (LA)) play critical roles in inducing breast tumors [45]. Arachidonic acid
has been termed as pro-neoplastic fatty acid [46] because of its role in inflammation,
cell proliferation, apoptosis, metastasis, and angiogenesis [47]. AA is associated with
membrane phospholipids that originate from LA present in the fatty diet. Incidentally, LA
is an unsaturated fatty acid (C18: 2) and can be imported into cells by different fatty-acid
binding proteins (FABPs) [48; 49; 50]. The LA, once internalized, undergoes
desaturation and elongation to produce dihomo gamma linolenic acid (DGLA) before
transforming into AA [51]. The DGLA passes through another desaturation catalyzed by
5-desaturase for the formation of AA. The important factor in this conversion is the
availability of microsomal 6-desaturase enzyme [52]. Arachidonic acid synthesized
through this reaction is incorporated into the membrane phospholipids and can be
released by the action of phospholipase A2 (PLA2) [53]. Phospholipase A2 (PLA2) is
divided into Ca2+-dependent, Ca2+-independent and secretory PLA2s. The Ca2+dependent cytoplasmic PLA2s (cPLA2) and secretory PLA2s participate in releasing AA
from the arachidonoyl-phospholipid in normal and cancer cells, which immediately
reacts to endogenous cycloxygenase, lipoxygenase, or cytochrome p450 to produce
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eicosanoids [54]. As mentioned above, eicosanids are associated with many different
physiological and pathological outcomes, including inflammation, leukocyte infiltration,
cell proliferation etc.
Breast cancer cells synthesize excess prostaglandin E2 (PGE2) and also over-express
the corresponding receptor molecules (i.e., the PG receptors). Prostaglandin (PG)
receptors are the members of G-protein-coupled receptors (GPCRs) and are involved in
generating downstream signaling pathways that are involved in the angiogenesis and in
alterations in cell adhesion, morphology, motility, invasion, and metastases [55].
Currently, there are eight known PG receptors of different cell types, which are PGD2
receptor (DP2), four subtypes of PGE receptors (i.e., EP1, EP2, EP3, and EP4), the
PGF receptor (FP), the PGI receptor (IP), and the TXA receptor (TP). PGE 2 is the major
secretory product of breast tumor epithelial cells and is found in fibroblasts,
macrophages, and lymphocytes at the tumor site. Higher levels of PGE2 are correlated
with cancer aggressiveness and metastatic potential [55]. PGE2 stimulates estrogen
biosynthesis and influences the progression of the cancer [56]. It also stimulates
expression of the aromatase gene CYP19 by activating protein kinase A and protein
kinase C signaling pathways. CYP19 is responsible for estrogen biosynthesis in breast
cancer affecting breast tumor development and growth, [57]. On the other hand, LT
formation corresponds to cellular growth, leukocyte infiltration, and DNA synthesis in
cancer cells [58]. Excess LT syntheses and 5-lipoxygenase over-expression have been
reported in colorectal cancer and lung cancer. It is interesting that the specific
lipooxygenase (LOX) inhibitors have the potential to reduce tumor growth and
metastasis [59]. The presence of BLT (B leukotriene receptor) receptors in the
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membrane is important for binding with secreted leukotriene B4 (LTB4) and for autocrine
signaling. LTB4 mediates the inflammatory responses in the target cells by activating the
phosphorylation of NF. Studies suggest that BLT1 is present in lipid rafts (LRs) in the
membrane, and disruption of LRs can potentially inhibit the pro-inflammatory responses
generated by LTB4 [60]. LRs are the membrane-bound lipid domain responsible for the
endocytosis of different molecules and ligands. Rafts are characterized in different
species and have been shown to play an important role in cellular metabolism and
synthesis. Cancer cells having an increased amount of metabolic rate have elevated raft
formation, resulting in active transportation machinery compared with normal epithelial
cells. Raft-specific markers such as monosialo ganglioside (GM1) [61], flotilin [62],
caveolin [63], mmp-9 [64], uPAR [65], etc., are over-expressed in various cancer cell
lines. Figures 8A, 8B, and 8C show the role of lipid rafts in the cancer process by
activating various pro-metastatic signaling events [66].

1.5. RECENT DEVELOPMENTS IN BREAST CANCER THERAPEUTICS

Therapeutic strategies to treat breast cancer patients depend on the detection and
diagnosis. The results obtained from these diagnoses guide the physicians to prescribe
a course of anti-estrogen (e.g., tamoxifen) or anti-progesterone (e.g., CDB 4124) or
anti-HER2 (e.g., trastuzumab)-based therapies along with adjuvant and sometimes
traditional chemotherapeutic compounds (e.g., microtubule disruptors, nucleoside
analogues, or radiations). These anti-receptor antibodies or analogues would counteract
the elevated levels of the specified receptor proteins, but in the majority of cases the
26

disease is diagnosed in the late stage, and therefore the treatment cannot rely solely on
a specific drug or antibody. Microtubule destabilizing drugs, along with suitable antihormonal therapy, are used to produce a more effective therapeutic strategy—e.g., DM1 (thiol-containing maytansinoid antimicrotubule agent), along with trastuzumab (antiHER2 antibody). Aromatase inhibitor has also been widely used to inhibit the estrogen
synthesis in cases of estrogen-positive breast cancer among post-menopausal women.
Examples of aromatase inhibitors are exemestane (aromasin), anastrozole (arimidix),
etc., and these drugs are sometimes associated with other chemotherapeutic agents
such as tamoxifen or gemcitabane (nucleoside analog) to produce a combinatorial drug
treatment against estrogen-sensitive breast cancers.
Recent advances in oncogenic drug discovery led to the use of antibody-based therapy.
The best example would be HerceptinTM(trastuzumab) from Genentech, which is an
antibody against the HER2 receptors. This antibody binds to the specific receptor and
can deactivate the receptor function. Yet, there is always the possibility of developing
other factors that are essential for maintaining the carcinogenic status of an individual,
such as the dimerization of receptor proteins to escape the therapeutic interventions.
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Figure 7
Lipid raft/caveolin and cancer cell signaling
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Figure 7. Lipid raft/caveolin and cancer cell signaling
Figure 7A shows the role of a lipid raft protein, caveolin-1 in the initiation of cellular
invasion and metastasis mediated by a high Rho activity and a low Rac activity.
Caveolin-1 overexpression causes the extracellular matrix remodeling which favors
tumor metastasis [66]. Figure 7B demonstrates the various lipid raft molecules, neuronal
Wiskitt-Aldrich syndrome protein (N-WASP), Matrix metalloproteinases (MMP),
cholesterol and their participation in the formation of invadopodia in cancer metastasis
[67].
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Table-3
Clinical Trials Recent clinical trials. Some of the major clinical trials in breast
cancer are described in Table-3 along with the targeted pathways.
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1.6. FOCUS OF MY RESEARCH

In the present study, I demonstrate that while AA treatment of invasive MDA-MB-231
breast cancer cells inhibits the synthesis of various PGs, it induces the production of
LTB4, HETE-5, and HETE-8 molecules. Results also show that LTB4 modulates the
migration of cancer cells by activating NF-linked pro-inflammatory cytokines (IL-6 and
IL-8) and caveolae. Nordihydroguaiaretic acid (NDGA), a common lipoxygenase
inhibitor is able to decrease the synthesis of LTB4 and inhibits the NF, IL-6, and IL-8
syntheses. Methyl-cyclodextrin (MBCD), a known LR disruptor, interferes with LR
biogenesis and with the migration of MDA-MB-231 cells. Overall, invasive breast cancer
cells exhibit increased inflammatory and metastatic migration/invasion upon the addition
of exogenous AA. A novel leukotriene (LT)-mediated activation of inflammatory
response/migration via the lipid raft microdomain was proposed in the current
dissertation.

1.7. HYPOTHESIS

Arachidonic acid promotes metastatic migration and invasion of breast cancer cells by
regulating leukotriene-induced inflammatory pathway.
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1.8. DISSERTATION GOALS

The overall goals of this work are to understand the arachidonic acid (AA)-induced lipid
signaling in invasive and non-invasive breast cancer cells and to identify important lipid
mediators that facilitate this process. Epidemiological studies support the idea that the
consumption of a high-lipid diet could lead to different physiological malfunctions, which
can ultimately produce malignancy. Therefore, an attempt has been made to understand
the key factors affected by AA in invasive and non-invasive breast cancer cells by
addressing the following questions.
1.

Does AA influence the eicosanoid synthesis in invasive and non-invasive breast
cancer cells differently, and if so, how does that affect the migration and invasion
processes?

2.

How does AA-induced eicosanoid synthesis modulate the inflammatory reactions in
breast cancer cells?

3.

Are there any connections among AA-induced eicosanoid productions, inflammatory
reactions, activation of lipid rafts, and metastatic migration/invasion of breast cancer
cells?

I hope that addressing these questions, at least in part, should unravel some of the key
mechanisms by which bioactive lipid mediators regulate the initiation and progression of
breast cancers that affect millions of women worldwide every year.
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CHAPTER 2

SPECIFIC AIM 1
TO INVESTIGATE THE MODULATION OF EICOSANOID SYNTHESES
BY ARACHIDONIC ACID IN INVASIVE AND NON-INVASIVE BREAST
CANCER CELLS.
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2.1. INTRODUCTION
The relationship between the high-fat diet and the incidence of cancers is now well
established. Diets enriched with polyunsaturated fatty acids (PUFA) are one of the risk
factors for breast, colon, and prostate cancers [68; 69; 70]. Among different PUFAs, the
omega-6 fatty acids, especially the AA and omega-3 fatty acids (e.g., eicosapentanoeic
acid) play pivotal roles for maintaining the cellular homeostasis and inflammation [71].
Omega-6 fatty acids are known to stimulate the inflammatory reactions because they
are involved in synthesizing the inflammatory eicosanoid molecules such as PGs, LTs,
TXs, and HETE compounds as shown in Figures 9 and 10. The inflammatory
eicosanoids include 2- and 4-series molecules (e.g., PGE2, LTB4, etc.), whereas 3- and
5-series compounds, which are derived from omega-3 fatty acids, are anti-inflammatory
(e.g., PGE3, LTB5, etc.).
Dietary PUFAs, once taken up by cells, are incorporated (esterified) into membrane
phospholipids followed by the hydrolysis by phospholipase A 2. Free fatty acids
(unesterified FFA) that are released from the membrane are then metabolized by two
major pathways in the cell to synthesize various eicosanoids by cyclic (cyclooxygenasemediated) and/or by linear (lipoxygenase-mediated) pathways [72].
2.1.1 Cyclic pathway
Cycloxygenase (COX-1 and COX-2) enzymes use free AA to produce various
eicosanoids such as PGs, prostacyclins, and TXs (Figure 9A). The COX-1 is
constitutively expressed in mammalian cells at a low level, whereas COX-2 is inducible
and is often over-expressed under stimulation. Prostaglandins (PGs) were first isolated
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from the semen, and the name signifies that these molecules originate from the prostate
gland [73].
PGs are unsaturated carboxylic acids (with a 20-carbon skeleton because they are AA
derived) and made of a five-member ring. They are sub-classified based on the nature
and position of a specific substituent on the ring. Prostaglandin A (PGA), prostaglandin
E (PGE), prostaglandin J (PGJ), prostaglandin F (PGF), and prostaglandin K (PGK) all
have keto groups in various locations on the ring, and they are distinguished from one
another because of the positioning of double bonds and hydroxyl groups in the
molecules [74]. For example, PGF has two hydroxyl groups, while PGK has two keto
groups. Prostacyclins (known as PGIs) are characterized by an oxygen bridge between
carbons 6 and 9. Another COX-mediated eicosanoid, thromboxane A (TXA), contains
an unstable bicyclic oxygenated ring structure, while thromboxane B (TXB) has a stable
oxane ring.
PGs are associated with activation of the inflammatory response, production of pain,
and fever [75]. Thromboxane stimulates constriction and clotting of platelets [76].
Leukocytes infiltrate to the site of tissue injury to minimize tissue destruction and
synthesize PGs. PGE2 promotes uterine contractions and is applied to induce labor.
PGs are also involved in several other organs such as the gastrointestinal tract (they
inhibit acid synthesis and increase secretion of protective mucus), and they increase
blood flow in the kidneys. PGE2 secretion is highly regulated in colon cancer, pancreatic
cancer, and different metabolic disorders [77; 78] Anti-inflammatory medications such
as aspirin block COX enzymes and inhibit the oxygenation of arachidonic acid
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conversion to prostaglandins. Blocking the syntheses of PGs relieves the pain and
fever.
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A. Cyclic pathway

B. Linear pathway

C. Nordihydroguaiaretic acid (NDGA)

Figure 8
Cyclic and linear pathways of arachidonic acid and eicosapentaenoic
acid metabolism in mammalian cells
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Figure 8. Cyclic and linear pathways of arachidonic acid and eicosapentaenoic
acid metabolism in mammalian cells
Figure 8A is an overview of eicosanoids synthesized from arachidonic acid (omega-6)
and eicosapentaenoic acid (omega-3) by the cyclic pathway. The metabolic products
from these pathways are, PGE2, PGF2, PGE3, PG3, PGA, PGB, PGC, PGD, PGG,
PGH, PGJ, PGK, TX-A and TX-B. The metabolic by-products from linear pathway are
shown in Figure 8B. The products are LTA4, LTB4, LTC4, LTD4, LTE4, 5-HETE, 8-HETE,
12-HETE and15-HETE. Figure 8C depicts the chemical structure of a lipoxygenase
inhibitor nordihydroguaiaretic acid (NDGA).
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2.1.2 Linear pathway
LTs and HETE compounds are synthesized by the linear pathway (Figure 9B). Different
lipoxygenase enzymes (e.g., 5-LOX, 12-LOX, 15-LOX, etc.) catalyze the oxygenation of
free fatty acids to synthesize LTs and HETE compounds [15]. Upon stimulation, the
cellular 5-LOX enzyme translocates to nuclear membrane and co-localizes with 5-LOX
activating protein (FLAP) and cPLA2. This interaction converts free AA to 5(S)hydroperoxy-6, -8, -11, -14-eicosatetraenoicacid (5-HPETE). This 5-HPETE can be
reduced to form 5-HETE compounds [54]. The 5-LOX enzyme in the presence of FLAP
hydrolyzes AA to synthesize LTA4, which is further hydrolyzed to LTC4 and then to
LTB4, which is secreted by the cells and causes vasoconstriction, allergic reaction,
hypersensitivity, and inflammation [79]. Subsequently, 8-LOX, 12-LOX, or 15-LOX
oxidized AA to synthesize 8-, 12-, and 15-HETE compounds, which are also associated
with various types of cancer [80; 81]. Anti-asthma medications include 5-LOX inhibitors
to inhibit the synthesis of LTs. Figure 9C represents the structure of a commonly used
biphenolic LOX inhibitor, nordihydroguaiaretic acid (NDGA).

The effect of LT formation corresponds to cellular growth and DNA synthesis in cancer
cells, and LOX inhibitors are reported to reduce tumor growth and metastasis [58; 59].
Recently, it has been demonstrated that LTB4 is able to induce growth and subtumorigenic inocula of melanoma cells [82]. Inhibition of 5-LOX induces apoptosis in
prostate cancer cells by down-regulating protein kinase C enzyme [83]. Another
contemporary finding by Cheon et al. [84] showed a pro-tumorigenic role of
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hematopoietic 5-LOX in inducing colorectal polyposis. Guo et al. [85] showed the
connection between oral cancer and elevated 5-LOX activity.

The LOX products from linear pathway of AA metabolism transduce signals by specific
membrane-bound receptors [86]. LTB4 primarily binds to the G-protein-coupled
receptors called BLTs—i.e., BLT-1 and BLT-2. BLT-1 is the primary receptor for LTB4,
and inhibiting the activity of these receptors shows a positive regulatory effect for the
prevention of carcinogenesis. Ihara et al. [87] found a remarkable expression of BLT-1
in human colon cancer cell lines. BLT-2, the low-affinity LTB4 receptor, is up-regulated
-

in estrogen receptor negative (ER ) breast cancer cells and has been noticed to work in
tandem with reactive oxygen species (ROS) to generate pro-survival signaling [88].
Ovarian cancer patients showed a high level of expression of LTB4 and BLT-2 [89].
Another recent work by Hu et al. [90] suggested a feedback loop involving FASN/pERK/5-LOX/ and LTB4 in the growth of metastatic breast cancer cells.

2.2. MATERIALS AND METHODS
2.2.1. Cell culture and treatments
MDA-MB-231 (Figure 10A) and MCF7 (Figure 10B) were cultured in DMEM/Ham´s F-12
and RPMI-1640 medium (Gibco Invitrogen, Carlsbad, CA), supplemented with 10% fetal
bovine

serum

(10%

FBS,

Atlanta

Biologicals,

Lawrenceville,

GA)

and

1%

penicillin/streptomycin (Hyclone, UT). Cells were grown in a humidified atmosphere
consisting of 95% air and 5% CO2 until they reached ~90% confluency. Confluent cells
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were treated with trypsin (0.25% Trypsin-EDTA, Hyclone), harvested by centrifugation,
and plated in either 96-well plates (~20,000 cells per well) or 6-well plates (0.5 X 106
cells per well) to perform either MTS assay or Western blot analyses. To evaluate the
toxic effect of AA, cells were treated with various concentrations of AA (Sigma-Aldrich,
St. Louis, MO) (10–300 M) for 24 h.
To perform eicosanoid extraction, cells were plated in a 6-well plate (~0.5 X 106 cells
per well) and were grown overnight. Fresh media (2 ml) was added to each well and
incubated for an additional 24 h in the presence of AA (100 M), NDGA (10 M), or AA+
NDGA (100 M + 10 M).

2.2.2. Dose response
MCF7 and MDA-MB-231 cells were plated (~20,000) in 96-well plates and grown
overnight. The cells were treated with different concentrations of AA (e.g., 10 M, 25
M, 50 M, 100 M, 200 M, and 300 M) for 24 h to find a concentration that did not
exhibit any toxic effects and that was safe for conducting the in-depth investigations
described in this and other chapters of my dissertation. Hydrogen peroxide (H2O2) was
used as a positive control. A dye containing methyl-tetrazolium salt (MTS) was added to
each well of a 96-well plate and incubated for an additional 30 min at 37 oC. The
absorbance of the well plate was measured in a microplate reader at 590 nm.
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2.2.3. Apoptosis assay
I also evaluated the effect of AA on inducing the apoptosis of MDA-MB-231 and MCF-7
cells. For this, cells were cultured in 6-well plates for 24 h and treated with various
concentrations of AA (10–300 M). Whole cell lysates were prepared and were
subjected to perform the immunoblot analysis to measure the activation of polyadenyl
ribose polymerase (PARP). Anti-PARP antibody (Cell Signaling Technology, Danvers,
MA) was used to detect the expression of full-length (~110 KD) and cleaved PARP (~89
KD) protein.

2.2.4. Analyses of eicosanoid by reverse–phase, high-performance liquid
chromatography (RP-HPLC)
MDA-MB-231 and MCF7 cells were grown in 6-well plates until they reached 90%
confluency before treating with AA in the presence or absence of NDGA for 24 h. Cells
were separated from the medium, and eicosanoids were extracted using ethyl acetate
extraction as described before [91]. The samples were vortexed and centrifuged at
3,000 rpm for 10 min. The top layer containing ethyl acetate was transferred to a Teflonlined vial and dried under N2 gas. The dried samples were resuspended in 40 l of
methanol and stored at -20 oC for further analysis by HPLC (Waters, Inc., Milford, MA).
Different eicosanoid standards were analyzed before assessing the eicosanoids from
individual samples. The elution times of the eicosanoids were as follows: PGE2, 60 min;
PGD2, 64 min; LTB4, 72 min; HETE5, 85 min, and HETE8, 90 min.
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Samples were mixed with acetonitrile (1:1,000) and subjected to HPLC following the
method of Moraes et al. [92]. Eicosanoids were eluted with the help of a trifluoroacetic
acid (0.1%)-acetonitrile solvent system (flow rate: 0.4 ml/min). Individual eicosanoids
were quantified by calculating the areas covered under each peak using EMPOWER
software (Waters, Inc., Milford, MA).

2.2.5. Statistical analyses
All results were expressed as the means ±SD. Statistical analysis was performed using
Microsoft Excel (2007) software, and the student’s t tests were carried out to assess the
mean differences between the treatment and control. Values were considered to be
statistically significant when p < 0.05.*
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A
Triple negative (TNBC) MDAMB-231 (invasive drugresistant cancer cells)

B
Estrogen receptor positive
(ER+) MCF7 (drug-sensitive
non-invasive cancer cells)

Figure 9
Breast cancer cell images
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Figure 9. Breast cancer cell images
Figure 9A and 9B represent the cellular images of MDA-MB-231 and MCF7 cells
respectively. MDA-MB-231 is a triple negative, invasive and fibrous-like breast cancer
cells, whereas MCF7 is estrogen receptor positive and minimal invasive luminal
epithelial cells. Bar: 20M
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2.3. RESULTS
2.3.1. AA and cellular toxicity
Arachidonic acid (AA) is a polyunsaturated fatty acid and a major component of red
meat, vegetable oil, etc. We performed a dose-response assay to evaluate the toxic
effect of AA on two cancer cell lines, MDA-MB-231 and MCF-7. The cells were briefly
treated with various concentrations of AA (i.e., 10, 25, 40, 100, 200, and 300 M) for 24
h and subjected to MTS assay to determine the cytotoxic effects of AA [93]. I found that
the IC50 (i.e., the half-maximal inhibitory concentration) of AA was ~200 M in both
MDA-MB-231 and MCF7 cells (Figures 11A and 11B). However, 100 M AA was used
in the current study, which was much lower than the concentration at IC 50, and no
cytotoxicity was observed at this concentration of AA.
Because AA is known to induce apoptosis, and because of the reason that 100 M AA
was used in this experiment, I asked what doses of AA could induce the apoptosis in
these two breast-cancer cells. Polyadenyl ribose polymerase (PARP) assay was
performed to identify the dose at which AA can induce the apoptosis in MDA-MB-231
and MCF-7 cells. Full-length PARP protein (PARP-I, ~116 KD) is constitutively
expressed in a majority of mammalian cells, and during apoptosis activated caspase-3
cleaves PARP into a relatively smaller fragment (~89 KD). The result, shown in Figure
11C, revealed that a 200-M concentration of AA can induce the cleavage of PARP-1
with caspase-3, which is a determinant of the activation of an apoptosis cascade. These
results suggested that AA at 100-M concentration was safe for conducting the
experiments described in this and the following chapters. Furthermore, other
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laboratories also used 100 M AA for studying the signaling events in cancer and other
cells [94; 95].
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A

B

Figure 10
Dose response assay
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Figure 10. Dose-response assay
MDA-MB-231 and MCF7 cells were cultured in 96-well plates and treated with various
concentrations of arachidonic acid (indicated in the figure) for 24 h and the viability was
tested by 3-(4,5-dimethyl thiazol-2yl)-5-(3-carboxymethhoxyphenyl)-2-(4-sulfophenyl)2H-tetrazolium (MTS) assay. MTS compound is bio-reduced by viable cells into a
reddish brown colored formazan product. The optical density (OD) of formazan product
is measured at an absorbance of 490nm. The OD value is directly proportional to the
number of viable cells.
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Figure 11
PARP assay
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Figure 11. Poly ADP-ribose polymerase (PARP) assay to monitor apoptosis
MDA-MB-231 and MCF7 cells were cultured in 6-well plates and treated with various
concentrations of arachidonic acid (AA) for 24 h, cell lysates were prepared and PARP
cleavage assay was carried out by immunoblot analysis to assess the apoptosis. The
generation of cleaved ~89kD PARP from ~116 kD precursor protein by 200 M AA
treatment is clearly visible.
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2.3.3. Effect of AA on eicosanoid syntheses
Even though the incorporation and release of AA from membrane phospholipids are
critical for the production of various eicosanoid molecules, it is not clear how
exogenously administered AA modulates eicosanoid synthesis in invasive and noninvasive breast cancer cells. To address this, invasive breast cancer MDA-MB-231 and
non-invasive MCF7 cells were tested for eicosanoid synthesis under the influence of
AA.
The syntheses of various eicosanoids by MDA-MB-231 and MCF7 cells (control and AA
treated) were analyzed by reverse phase HPLC, and the areas under each eicosanoid
peak were quantified using the integration software EMPOWER 3 (Waters, Inc.,
Milford, MA). HPLC profiles of different eicosanoids in the control cells are
demonstrated in Figures 12A and 12B. The quantitative assessment in Figure 12C
shows that MDA-MB-231 synthesizes a higher level of PGE2 and PGD2 than MCF7. In
contrast, the basal levels of LOX products___i.e, LTB4, 5-HETE, and 8-HETE—are
higher in MCF7 than MDA-MB-231. Interestingly, the AA treatment (100 M)
suppressed the synthesis of all eicosanoids in MCF-7 cells, but in MDA-MB-231 it
down-regulated PGE2 and PGD2 and stimulated the syntheses of LTB4 and 8-HETE.
Figure 12D shows that AA induces a ~4-fold increase in LTB4 production in MDA-MB231, and this could be blocked by NDGA (10 M), an inhibitor of LT synthesis.
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B

Figure 12
Classes of eicosanoids synthesized by MDA-MB-231 and MCF7 cells
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C

D

Figure 12
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Figure 12. Classes of eicosanoids synthesized by MDA-MB-231 and MCF7 cells
MDA-MB-231 and MCF7 breast cancer cells were cultured in a growth medium
supplemented with fetal bovine serum (FBS, 10%) and cultured until the cells reached
confluency (~70–80%). Fresh medium was added to the confluent monolayer and
treated with 100 M AA, 10 M NDGA (a 5-LOX inhibitor), and 100 M AA+ 10 M
NDGA for 24 h as described in the Materials and Methods section of this chapter.
Secreted eicosanoids were extracted from the media and analyzed by highperformance liquid chromatography (HPLC). Figures 12A and 12B show the HPLC
profiles of eicosanoids from MDA-MB-231 and MCF7 cells, respectively. Figure 12C
demonstrates the effects of AA (100 M) on their syntheses. Figure 12D represents the
LTB4 levels in the two cell lines after AA and NDGA treatment. All experiments were
repeated at least three times, and the data are given as means ± SE; *p < 0.01, ** p < 0.
001. PGE2, prostaglandin E2; PGD2, prostaglandin D2; LTB4, leukotriene B4; HETE,
hydroxyeicosatetraenoic acid.

55

2.4 CONCLUSION
The goal of Chapter 2 was to provide understanding of how AA, which is a substrate of
eicosanoids, modulates the activities of COX-2 and LOX enzymes. I found that AA at
100 M inhibits the synthesis of COX-2 products but activates two LOX products (LTB4
and 8-HETE) in MDA-MB-231 cells. In contrast, AA inhibits the synthesis of both COX-2
and LOX products in MCF-7 cells. Therefore, I hypothesize that the increased synthesis
of LTB4 and 8-HETE in MDA-MB-231 cells under the influence of AA could be an
indication of the changes of the catalytic function of LOXs that allows these groups of
enzymes to become hyperactive in invasive breast cancer cells. It is also possible that
AA at 100 M inhibits the catalytic function of COX-2 by an “excess-substrate-inhibition”
mechanism that allows the cells to utilize higher concentrations of AA by activated LOX
pathways to avoid the toxic effect. The importance of 5-LOX in breast cancer
malignancy (as predicted in the current study) can be further supported by the reports
from other cancers. For example, elevated activity of 5-LOX is associated with the
progression of hepatocellular carcinoma [96], and it also promotes polyposis formation
in the intestine [84]. Earlier studies indicated that COX-2 plays an essential role in the
development of various forms of cancer and that the mutation in COX-2 genes
promotes colorectal carcinogenesis [54]. Interestingly, my results, along with the reports
from other laboratories [84; 96], strongly supports the idea that LOX pathway is equally
important and involved in the growth and malignancy of breast cells. In fact, a recent
study by Wen et al. [97] suggested the role of LTs in breast cancer development and
reported an increased activity of 5-LOX with concomitant reduction of COX-2. In

56

Chapters 3 and 4, I have investigated the pathways by which AA and LTB 4 induce
inflammatory reactions and metastatic invasion of MDA-MB-231 breast cancer cells.
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CHAPTER 3

SPECIFIC AIM 2
TO EXAMINE WHETHER AA AFFECTS THE PRO-INFLAMMATORY
PATHWAYS, CELLULAR MIGRATION, AND INVASION IN CULTURED
BREAST CANCER CELLS.
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3.1. Introduction

Inflammation, migration, and invasion of cancer cells are associated with the activity of
extracellular-matrix ligands and signals necessary for locomotion [66; 98]. Migration
facilitates the cancer cells in invading the surrounding tissue and colonizing a new site.
Thus, migration and invasion by a cancer cell represent an important step in the spread
of the disease across tissues and lymphatic nodes, which are often referred to as
metastasis. The mechanisms of cell migration involve complex interactions among
various proteins and signaling molecules, activation of focal adhesion kinase (FAK),
actin polymerization, lammellopodia formation, and the involvement of extracellular
matrix as well as integrin molecules [7; 99]. Reports suggest that various environmental
factors, carcinogens, hormones, and fatty acids, including AA, can influence the
migration of various cells, including those of breast cancer [8; 9]. AA can activate the
nuclear factor kappa beta (NF-mediated inflammatory pathway, which subsequently
can degrade the extracellular matrices and promote angiogenesis (Figures 13A and
13B). Studies also suggest that AA promotes the adhesion and migration of endothelial
cells and can act as a regulator of wound healing and angiogenesis [8; 100]. The level
of PGE2, a major product of COX-2 reaction, is elevated in breast cancer cells and
functions as a pro-tumorigenic agent [101; 102]. COX-2-dependent PG synthesis has
been shown to be involved in maintaining the motility and invasion of breast cancer cells
[103; 104], and the inhibitor of COX-2 could block the radiation-induced migration of
MDA-MB-231 cells [105], suggesting that the COX-2 pathway is important and is
involved in the invasion and metastatic migration of breast cancer cells. Like COX
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pathways, LOX-derived eicosanoids are also involved in tumor formation and
malignancy [106; 107], although many of their roles in inducing migration and
metastasis of breast cancer cells are not well understood. In Specific Aim 1 (Chapter 2),
I demonstrated that while AA stimulates the production of LTB4, it inhibits the synthesis
of PGs and other eicosanoids in MDA-MB-231 cells. 5-LOX is a member of the LOX
family of enzymes that synthesizes LTA4, LTB4, LTC4, LTD4, and LTE4 [108]. LTB4, a 4
series of eicosanoids, is synthesized from unstable LTA4 by the action of LTA4
hydrolase. LTB4 is a powerful bioactive lipid that is involved in various physiological and
pathological functions, stimulates the cells via autocrine and paracrine signaling, and
acts through the LTB4 receptor (known as the BLT receptor). LTB4 has a role in the
anaphylectic reactions and is responsible for different lung cancer pathologies [109],
and it can stimulate the proliferation of pancreatic cancer cells [110]. In a recent study, a
high concentration of exhaled LTB4 and IL-8 were shown to be associated with the
neutrophilic inflammation in the airways of lung cancer patients [109], and a protumorigenic effect of LTB4 in melanoma cells has also been reported [82]. Recently,
Guo et al. have shown that the activation of the 5-LOX pathway is induced in ethanolinduced oral cancer [85]. Likewise, the inhibition of 5-LOX induces apoptosis in prostate
cancer cells by down-regulating the activity of protein kinase C [83]. Another recent
finding by Cheon et al. [84] suggested a pro-tumorigenic role for hematopoietic 5-LOX in
the immune microenvironment and recommended 5-LOX inhibition for the treatment of
colorectal polyposis and cancer. A direct association between increased 5-LOX activity
and the progression of hepatocellular carcinoma and intestinal polyposis strongly
suggests that it plays a role in inflammation, tumor promotion, and metastasis [84; 96].
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The goal of Specific Aim 2 is to delineate the inflammatory pathways that are stimulated
by excess LTB4 and how they are linked to the migration and invasion of MDA-MB-231
cells.
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Figure 13
Inflammation and tumor microenviornment
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Figure 13. The Inflammation and microenvironment of tumor cells
Figure 13A illustrates the Ik and NF-mediated inflammatory responses in cancer
cells. Cellular inflammation causes the activation of NF which subsequently activates
the transcription of cytokines, chemokines and adhesion molecules which all together
promotes the process of tumorigenesis [111]. Figure13B suggests the IL-8 mediated
neutrophil recruitment, stimulation of macrophage derived growth factors and adhesion,
migration and invasion by cancer cells [112].
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3.2. MATERIALS AND METHODS

3.2.1. Cell culture and treatments
MDA-MB-231 and MCF7 were cultured in RPMI-1640 and DMEM/Ham´s F-12 medium
(Gibco Invitrogen, Carlsbad, CA). Both RPMI and DMEM were supplemented with 10%
fetal

bovine

serum

(Atlanta

Biologicals,

Lawrenceville,

GA)

and

1%

penicillin/streptomycin (Hyclone, Logan, UT). Breast cancer cells were grown in a
humidified atmosphere (95% air and 5% CO2) until they reached ~90% confluency.
Confluent cells were treated with trypsin (0.25% Trypsin-EDTA; Hyclone), harvested by
centrifugation, plated on a 6-well plate (~0.5 X 106 cells per well) and treated with AA
(sodium salt, 100 M; Sigma) for 24 h with or without prior treatment with the LOX-5
inhibitor nordihydroguaiaretic acid (NDGA, 10 M; Sigma). Control and treated cells
were collected, washed, and subjected to further analyses as described in the text.
3.2.2. Immunoblot analyses
Control and treated cells were harvested, washed in cold PBS, and lysed by freezethaw in a lysis buffer, and the protein concentrations were measured with the help of a
protein assay kit manufactured by Bio-Rad (Hercules, CA). An equal amount of protein
(~40 g) was applied to each lane and subjected to electrophoresis in SDS-PAGE
(10%) followed by immunoblot analyses onto polyvinylidene fluoride (PVDF)
membranes as described previously by Albert et al. [113]. The PVDF membranes were
incubated overnight (6–10 oC) with anti-LOX-5 antibody (polyclonal; Gibco Invitrogen,
Carlsbad,

CA)

or

anti-GAPDH

(monoclonal;
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Glyceraldehyde

3-phosphate

dehydrogenase; Cell Signaling, Danvers, MA). The membranes were washed with
0.05% Tween-20 in Tris-Buffered saline (TBST) and incubated with horseradish
peroxidase (HRP)-conjugated goat anti-mouse and/or goat anti-rabbit IgG (KPL
Biomedical, Chantilly, VA). The enhanced chemi-luminescence (ECL) technique was
used for the detection of protein bands. The intensities of protein bands were measured
using Labworks software (UVP Lab Products, Upland, CA).
3.2.3 Confocal microscopy
MDA-MB-231 and MCF7 cells were grown in 4-well, chambered Lab-TEK II slides
overnight containing either RPMI-1640 or DMEM/F12 media. The cells were treated
with AA and/or NDGA and were fixed with methanol (100%, chilled) for 5 min at -20 oC
before being blocked with normal goat serum (NGS, 5%; Sigma) for 1 h. Methanol-fixed
cells were incubated overnight in the cold room with anti-5-LOX (1:200; polyclonal,
Cayman Chemical, Ann Arbor, MI) 1% NGS. The slides were washed three times and
incubated with fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit IgG,
mounted with ProLong® Gold antifade reagent mixed with DAPI (Gibco Invitrogen,
Carlsbad, CA). The confocal images were captured with the help of an LSM 700 Zeiss
confocal microscope and analyzed using Zen 2009 software (Carl Zeiss, Thornwood,
NY) as described earlier. Each experiment was repeated three times. Cells were
randomly selected from each slide using the same resolution, laser power, and
detector-gain. Student’s t tests were used to assess differences (means) between the
treatment and control; p < 0.05 was considered significant.
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3.2.4 Phospho-NFassay
To measure the levels of phospho-NFkB (p65), ~0.5 x 106 cells per well were plated in
6-well plates and cultured overnight. Cells were incubated for an additional 24 h in the
presence of AA (100 M), AA (100 M) + NDGA (10 M), or NDGA (10 M). Cell
lysates were prepared using the lysis buffer provided with the kit, and equal
concentrations of proteins were loaded in an antibody-coated, 96-well plate following
the instructions provided by the manufacturer. The absorbance of the samples was
measured using a microplate reader (Bio-Rad Laboratories, Hercules, CA) set at
450 nm. Values are expressed as relative optical density (OD) ± SD.

3.2.5. Analysis of IL-6 and IL-8 production
Approximately 1 x 105 cells were cultured in 12-well plates for the determination of IL-6
and IL-8 levels. Cells were treated with AA, AA + NDGA, or NDGA for 24 h as
mentioned above, and the supernatants were removed and centrifuged at 12,000 rpm
for 5 min. The concentrations of IL-6 and IL-8 in the culture supernatants were analyzed
by a commercially available enzyme-linked immunoassay kit (SA Biosciences, Qiagen,
MD) according to the manufacturer’s instructions. The absorbance was measured using
a microplate reader (Bio-Rad Laboratories, Hercules, CA) at 450 nm, a standard curve
was generated by plotting the optical density in y-axis against the amount (ng) of the
cytokines in the x-axis (i.e., OD vs ng/ml), and the amounts of interleukins present in the
samples were determined in ng/ml/105 cells ± SD.
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3.2.6. Cell migration and invasion assays
Migration of breast cancer cells was examined with the help of wound-healing assays,
which are standard procedure in monitoring cell migration and angiogenesis [8]. For
migration assays, ~0.5 X 106 cells were plated in each well of a 6-well plate and
incubated overnight in a medium (RPMI-1640 or DMEM) containing Fetal Bovine Serum
(FBS, 5%). It was observed that 5% FBS (instead of 0 or 10%) was optimal to monitor
the effect of AA-induced migration of MDA-MB-231 cells. The monolayers were
wounded by scratching with a sterile 10-L pipette tip [8], and they were treated with AA
(100 M), AA (100 M) + NDGA (10 M), NDGA (10 M), or methyl--cyclodextrin
(MBCD, 1 mM) for 24 h. The images of the cells that had migrated between wounded
regions were captured using a Nikon TMS microscope equipped with a Nikon F-601
camera, and they were counted. Each experiment was repeated for three times (n=3)
with multiple technical replicates.
Cell invasion assays, which represent the growth and metastatic migrations of cancer
cells, were carried out in Transwell chambers [114]. Briefly, cells were cultured in 12well plates (~3 x 105/well) for 24 h in the presence of AA, NDGA, and MBCD as
described above. Cells were harvested and suspended in 500 l medium containing 5%
FBS and added to the upper layer of Transwell chambers. The bottom wells were filled
with 1 ml of culture medium containing 10% FBS (to promote cell growth and invasion
through the matrigel of Transwell chambers). The cells that had migrated to the lower
chamber after 24 h of incubation were examined and photographed using a Nikon TMS
microscope equipped with a Nikon F-601 camera. Migrated cells were also stained with
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calcein (Invitrogen), a fluorescence dye that labels the viable cells. Both cell counts and
fluorescence intensities were taken into account to measure the invasiveness [115].
3.2.6. Statistical analyses
All results were expressed as the means ± SD. Statistical analysis was performed using
Microsoft Excel (2007) software, and student’s t tests were carried out to assess the
differences (means) between the treatment and control. Values were considered to be
statistically significant when p < 0.05.*
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3.3. RESULTS

3.3.1. Arachidonic acid stimulates 5-LOX expression in MDA-MB-231 cells

The 5-LOX is an essential enzyme of the AA pathway and is involved in the synthesis of
LTB4 and various cysteinyl-LTs, including LTC4, LTD4, and LTE4. Because AA
treatment increases the production LTB4 in MDA-MB-231 cells, we asked if AA
stimulates the expression of this enzyme in these triple-negative breast cancer cells. To
address this, AA-treated cells were analyzed by immunoblot (Figures 14A and 14B) and
confocal microscopy (Figures 14C and 14D) using anti-5-LOX antibody. Figure 14A
shows that while both cells express 5-LOX protein, only MDA-MB-231 responded to AA
treatment as far as the stimulation of 5-LOX is concerned. AA treatment induced the
synthesis of 5-LOX by ~2–fold, as evidenced by the densitometry analysis shown in
Figure14B, and this increased expression could be reduced by NDGA. In contrast, the
level of 5-LOX in MCF7 remained unaltered by AA and NDGA treatment. In fact, NDGA
alone stimulated the expression of 5-LOX slightly in MCF7 cells (Figures 14A and 14B).
The expression of 5-LOX was also monitored in MDA-MB-231 and MCF7 cells by
immunofluorescence microscopy. The results indicate that anti-5-LOX antibody reacts
with cellular LOX in both cells (as evidenced by green fluorescence), although the
fluorescence intensity in MDA-MB-231 is higher (~2-fold) than MCF7 (Figures 14C and
14D). Figure 14C shows that 5-LOX in spindle-shaped MDA-MB-231 cells are mostly
localized in the cytoplasm (photograph a). Upon stimulation by AA, the expression of 5LOX increases ~2-fold compared with the control, and a greater part of 5-LOX
translocates from cytoplasm to elongated extensions (photograph b). As shown in
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photograph c (Figure 14C), NDGA reduces the AA-stimulated 5-LOX reactivity
effectively (~4-fold). On the other hand, in MCF7, which exhibits dome-shaped
epithelial-like morphologies, 5-LOX expression increases slightly and is concentrated
mainly in the nucleus. Interestingly, NDGA shows minimal effects on 5-LOX reactivity in
MCF7 cells (Figures 14C and 14D).
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Figure 14
5-LOX expression in MDA-MB-231 and MCF7 cells
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D

Figure 14
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Figure 14. Arachidonic acid stimulates the expression of 5-lipoxygenase (5-LOX)
activity in MDA-MB-231 cells
MDA-MB-231 and MCF7 cells were cultivated in 6-well plates or 4-well chamber slides
containing growth medium for 24h and treated with either AA or AA+NDGA or NDGA as
described in Figure 12 before immunoblot and confocal microscopy analyses. Figure
14A demonstrates the expression ~79 KD 5-LOX in MDA-MB-231 and MCF7 in the
presence of AA (100 M) or NDGA (10 M) or AA+NDGA combination. Figure 14B
shows the densitometric analysis of each band shown in Figure 14A. Glyceraldehyde-3phosphodehydrogenase (GAPDH, ~37kD) was used as a loading control. Figure 14C
exhibits the cellular localization of 5-LOX in MDA-MB-231 and MCF7 cells in the
presence of AA and/or NDGA. For confocal analyses, the cells were fixed and labeled
with anti-5-LOX polyclonal antibody, and the images were captured with the help of a
Carl Zeiss Laser Scanning Confocal Microscope as described in the text. photograph a:
MDA-MB-231, control; photograph b: AA-treatment; photograph c: treatment with
AA+NDGA; photograph d: NDGA treatment; photograph e: MCF7control; photograph f:
AA treatment; photograph g: treatment with AA+NDGA, and photograph h: the
treatment with NDGA. Arrow denotes cytoplasm and asterisk indicates the nucleus. Bar:
10 M. The quantitative assessments of mean fluorescence intensity of 5-LOX in MDAMB-231 and MCF7 cells are shown in Figure 14D. All data represent the average of
three independent experiments. N = 3; * p < 0.01, ** p < 0.001
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3.3.2 Arachidonic acid elevates the levels of NF, IL-6 and IL-8 in MDA-MB-231
cells

Neoplasm is often preceded by inflammatory reactions before the characteristics of
malignancy are observed. Some of the key molecules that are shown to be associated
with cancer inflammation include various transcription factors and pro-inflammatory
cytokines [116]. The transcriptional factor NF, which is also a potential tumor
promoter, is considered to be an important modulator of innate immunity and
inflammation [117]. For example, NF is responsible for the activation of IL-6 and IL-8,
two pro-inflammatory cytokines in tumor cells [118; 119]. Because phospho-NF p65
(RelA) is known to be linked to the expression of cytokine genes, and because AA
activates 5-LOX expression (Figure 14), we asked whether AA also modulates the
expression of phosphorylated NF and pro-inflammatory cytokines. Figure 15A shows
that AA stimulates (~2-fold) the production of phospho-NF p65 and (ser 536) and that
NDGA blocks this stimulation. Compared with MDA-MB-231, however, MCF7 exhibits a
low level of phospho-NF expression and remains unaltered by AA or NDGA. Since
this transcription factor is linked to the expression of various cytokine genes, we
inquired as to whether interleukins and other inflammatory molecules are modulated by
AA. Various pro- and anti-inflammatory cytokines (i.e., IL-1A, IL-1B, IL-2, IL-4, IL-6, IL-8,
IL-10, IL-12, IL-17A, IFN and TNF) were measured using commercially available,
specific assay kits as mentioned in the Materials and Methods section. We observed
that except for IL-6 and IL-8 the majority of cytokines were either very low or could not
be detected (not shown). The results show that MDA-MB-231 cells produce higher
levels of IL-6 and IL-8 (~2- and ~5-fold, respectively) compared with MCF7, and that AA
74

increases the production of these two interleukins further (Figures 15B and 15C).
Interestingly, the induction of IL-6 by AA is more dramatic than it is for IL-8. As
expected, NDGA is effective in lowering the levels of both interleukins that were
stimulated by AA. NDGA by itself also showed some reduction of IL-6 and IL-8, and this
could be due to the fact that NDGA inhibits the metabolism of endogenous AA and
interferes with cytokine production. These experiments suggest that AA-induced 5-LOX
activation and LTB4 production are linked to NFIL-6 and IL-8 synthesis.
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Figure 15
Arachidonic acid stimulates the production of phosphoNFp65), IL-6 and IL-8
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Figure 15. Arachidonic acid stimulates the production of phospho- NFp65), IL6 and IL-8
MDA-MB-231 and MCF7 cells were cultured and treated with AA, AA+NDGA, or NDGA
before measuring the phospho-NFFigure15A), IL-6 (Figure15B) and IL-8 (Figure
15C) activities using commercially available assay kits as described in the methods and
materials. Data represent the average of three independent experiments. *p < 0.01,** p
< 0.001.

77

3.3.3 Arachidonic acid-induced LTB4 production is associated with the migration
and invasion of MDA-MB-231 cells

Metastatic migration of cancer cells is associated with the activity of extracellular-matrix
ligands and signals necessary for locomotion [98; 99]. Migration promotes the cancer
cells in invading the healthy tissue to form tumors. Therefore, we tested the possibility
that AA-induced LOX-5 activation and LTB4 synthesis facilitate the migration and
invasion of MDA-MB-231 cells. Briefly, MDA-MB-231 or MCF7 cells (MCF7 was used as
a negative control) were placed in a 6-well plate and incubated overnight as described
in Materials and Methods. The monolayers were wounded by scratching and were
cultured for 24 h in the presence and absence AA and/or NDGA before the counting of
the migratory cells. Figure 16A compares the migration of MDA-MB-231 cells across the
wounded region at 0 and 24 h of incubation in the culture plate (photographs a and b).
Photograph c (Figure 16A) shows that the number of migratory cells in AA-treated
plates increased ~2-fold and that NDGA blocked this increased migration significantly
(photographs d and e, Figure 16A). As expected, MCF7 cells showed little or no
migration across the wounded region (photographs f–j). Figure 16B measures the
number of migrated cells in the referred wounded region shown in Figure 16A. Side by
side with the migration assay, we also examined the invasion of matrigel by MDA-MB231 cells and asked whether this invasion could be influenced by AA. Invasion
capability was monitored in Transwell invasion chambers as described in Materials and
Methods. Cells were loaded into the upper chambers, incubated for 24 h, and the viable
cells that moved to the lower chambers were assessed by counting the cells with the
help of a microscope and testing their viabilities by labeling with calcein. Figure 17A
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demonstrates the number of MDA-MB-231cells (~80 cells/microscopic field) that
migrated to the lower chambers by crossing the matrigel, and this number increased in
the presence of AA by ~1.7-fold. NDGA blocked this invasion when treated with and
without AA. Data shown in Figure 17B further support the cell-count results (Figure 17A)
and indicate that the invading MDA-MB-231 cells are viable and that the number of
viable cells that migrated into lower chambers after AA treatment increased by ~1.5fold. As expected, NDGA reduced the migration of MDA-MB-231 cells into the lower
chambers (Figure 17B).
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Figure 16
The migration of MDA-MB-231 cells are induced by arachidonic
acid and blocked by NDGA
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Figure 16. The migration of MDA-MB-231 cells are induced by arachidonic acid
and blocked by NDGA
Approximately 1 X 106 cells were grown in a 6-well plate in growth medium
supplemented with 5% FBS. The cells (~70–80% confluent monolayer) were scratchwounded by a 10-M pipette tip and treated for 24 h with AA (100 M), AA (100 M) +
NDGA (10 M) or NDGA (10 M). The photographs were captured at 0 h and 24 h time
points as marked in the photographs. Figure 16A: photograph a: MDA-MB-231 at 0 h
wound-scratch; photograph b: 24 h; photograph c: migration at 24 h in the presence of
AA (100 M); photograph d: AA+NDGA (100 M + 10 M); photograph e: NDGA (10
M); photograph f: MCF7- at 0 h wound-scratch; photograph g; at 24 h wound-scratch;
photograph h: treatment with AA (100 M); photograph i: treatment with AA+NDGA (100
M + 10 M); and photograph j: NDGA-treatment (10 M). The cells migrated in the
wound-region were counted and are represented in Fig. 16B. All experiments were
repeated at least three times, and the data are given as means ± SE; *p < 0.01, ** p <
0.001.
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Figure 17
Arachidonic acid stimulates the invasiveness of MDA-MB-231 cells
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Figure 17. Arachidonic acid stimulates the invasiveness of MDA-MB-231 cells
Cells were cultured in a 12-well plate and were treated with AA (100 M), NDGA (10
M) as mentioned before. Cells were then harvested and suspended in 500 l medium
containing 5% serum and loaded on to the upper wells of a Transwell Chamber. The
bottom wells were filled with 1 ml of complete culture medium containing 10% serum.
The photographs of invading breast cancer cells in 24-h in the lower wells were
captured (Figure 17A) and counted from four different microscopic fields. Figure 17B
represents the average number of cells counted. The invaded cells in the lower wells
were stained with 2M of calcein and incubated for 30 min at room temperature. The
fluorescence of the viable cells was measured by fluorescence plate reader at an
excitation and emission of 490 and 520. Figure17C represents the mean fluorescence
of the viable wells. The results shown here are the average of two individual
experiments which were carried out in duplicate.
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3.4. CONCLUSION

The results depicted in Specific Aim 1 indicate that AA treatment suppresses the
syntheses of PGs in MDA-MB-231 and stimulates the syntheses of LOX products—e.g.,
LTB4 and 8-HETE—suggesting that the LOX pathway is equally important and activated
during malignancy. The increased synthesis of LTB4 in MDA-MB-231 cells under the
influence of AA could be an indication of the changes in the catalytic function of LOXs
that allow these groups of enzymes to become hyperactive in breast cancer. Thus, in
Specific Aim 2, I examined the effect of AA and NDGA (LOX inhibitor) on the secretion
of the pro-inflammatory cytokines IL-6 and IL-8, which showed a significant upregulation after AA treatment, whereas NDGA was able to inhibit the AA-induced IL6/IL-8 productions in MDA-MB-231 cells. It is interesting that invasive MDA-MB-231
cells exhibited higher levels of IL-6 and IL-8 than MCF7, suggesting a positive role for
these two cytokines in the inflammation invasion of breast cancer cells. I also made an
effort to investigate the stimulation of phospho-NFkB p65 (ser 536), which is known to
regulate the transcription of IL genes. I found that invasive cells (MDA-MB-231) show a
higher level of phosphorylation of NFkB compared with the non-invasive cells (MCF-7).
AA treatment shows the increase of NFkB phosphorylation, and NDGA inhibits this
process. Again, this finding shows, by modulating NFkB phosphorylation, the proinflammatory role of AA in breast cancer cells. These findings suggest that AA-mediated
activation of pro-inflammatory signaling in invasive breast cancer cells occurs via the 5LOX-mediated LTB4 synthesis and subsequent activation of NFkB and cytokine
secretion.
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Migration and invasion represent an important step in the metastasis and are often
referred to in trying to understand cellular aggression. After elucidating the role of 5LOX in the initiation of signaling cascade, I next demonstrated that AA promotes cellular
migration and invasion via LTB4. Increased production of IL-6 and IL-8 is either directly
or indirectly linked to migration and invasion by MDA-MB-231 cells. Earlier, AA was
reported [9] to increase the migration of MDA-MB-231 cells by activating focal adhesion
kinase (FAK), although the actual mechanism was not proposed. Thus, it can be
speculated that AA induces the migration of invasive breast cancer cells by activating
FAK via LTB4 and IL-6/IL-8 cytokines through a mechanism that is yet to be elucidated.
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CHAPTER 4

SPECIFIC AIM 3
TO UNDERSTAND WHETHER LIPID RAFT IS INVOLVED IN THE
LEUKOTRIENE B4- MEDIATED INFLAMMATION
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4.1. INTRODUCTION
Lipid rafts (LRs) are cholesterol and sphingolipid-rich membrane microdomains
responsible for generating intracellular signals downstream [120]. In addition to
sphingolipids and cholesterol, mammalian LRs also contain saturated fatty acids, cellsurface proteins, receptors, phospholipids, and glycosyl-phosphatidylinositol (GPI), as
demonstrated in Figure 1A. Various membranous proteins, such as caveolin, flotilin,
matrix metalloproteinase (MMP), etc., are compartmentalized in the raft domain and
play significant roles in the cell signaling process [121; 122; 123]. Cancer cells having
an increased amount of metabolic rates exhibit elevated LR formation, resulting in
active transportation machinery compared with the normal epithelial cells. LRs are
reported to promote the invasiveness and migration of cancer cells by facilitating
invadopodia and lamellopodia, although the actual mechanism is not yet clear [124].
Caveolae are subtypes of LRs, and they are composed of caveolins, an integral
membrane protein (Figure 1B). Caveolins make flask-shaped invaginations in the
membrane, called caveolae [125; 126]. The caveolin family consists of three different
isoforms in mammals—caveolin-1, -2, and -3 with caveolin-1 and -2 being expressed in
most of the tissues in mammals, whereas caveolin-3 is only expressed in muscle cells
[127]. Recently, Goetz et al. [66] reported that cellular metastasis in melanoma is
associated with the over-expression of caveolin in the fibroblasts. LR-mediated
endocytosis was shown to play a critical role in the regulation of cancerous cell growth,
signal transduction, apoptosis, adhesion, cell motility, and tumor metastasis [66; 128].
LR markers like caveolin, flotilin, MMP-9, mono-sialoganglioside (GM1), etc., are found
to be over-expressed and play a major role in tumor cell survival, aggression, and
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metastatic potential [129; 130; 131]. Antibodies against different LR markers are used
for identifying cellular LRs. GM1 is the most commonly used marker among various lipid
components of rafts; it is detected using the GM1-binding molecule cholera toxin
subunit B (CTxB).
LRs can be fractionated as detergent-resistant membrane (DRM) fractions by treating
with nonionic detergents (Triton X-100). Rafts enriched with cholesterol and sphingolipid
are insoluble in detergent, and they float in the low-density area during gradient
centrifugation [132]. Interestingly, it has been postulated earlier that the LTB4 receptor-1
(BLT-1) is located within the LRs of activated human neutrophils and that disruption of
LRs suppresses LTB4 syntheses [60]. Thus, to elucidate whether AA-mediated
signaling occurs through the LRs, we labeled LRs using anti-caveolin-1 or Ctx B
antibody. We hypothesized that LRs play an important role in the LTB4-mediated
signaling. We also addressed the question of whether LRs play any significant role in
cellular migration and invasion in breast cancer cells.
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Figure 18
Simplified 89
model of lipid raft

Figure 18. A simplified model of lipid rafts
Lipid rafts are membranous lipid microdomains, which is primarily consisting of several
lipid molecules such as sphingolipid, cholesterol, gangliosides, GPI anchored molecules
and transmembrane proteins (Figure18A) [133]. Figure18B demonstrates the formation
of a flask shaped specialized lipid raft called caveolae [134].
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4.2 MATERIALS AND METHODS
4.2.1. Cell culture and treatments
MDA-MB-231 and MCF7 cells were cultured in tissue culture flasks as previously
mentioned. Upon ~90% confluence, the cells were trypsinized and harvested. Then the
cells were plated in either a 6-well plate (~0.5 X 106 cells per well), 12-well plates, or 4well chamber slides to perform the immunoblot experiment, the cholesterol assay, and
confocal microscopy, respectively. The cells were treated with AA (sodium salt, 100 M;
Sigma) for 24 h with or without prior treatment with the LOX-5 inhibitor
nordihydroguaiaretic acid (NDGA, 10 M; Sigma), and the cells were also treated with
the lipid raft disruptor Methyl- cyclodextrin (MBCD, 1mM; Sigma). Control and treated
cells were collected, washed, and subjected to further analyses as described in the text.
4.2.2. Immunoblot analyses
Control and treated cells were harvested, lysed, and subjected to electrophoresis in
SDS-PAGE (10%), followed by immunoblot analyses on (polyvinylidene difluoride)
PVDF membranes as described in the previous chapter. The PVDF membranes were
incubated overnight (6–10oC) with anti-Caveolin-1 antibody (monoclonal, Santa Cruz
Biotechnology, Santa Cruz, CA) anti-Flotilin-1 antibody (monoclonal, Santa Cruz
Biotechnology, Santa Cruz, CA), or anti-GAPDH (monoclonal, Glyceraldehyde 3phosphate dehydrogenase, Cell Signaling, Danvers, MA). The membranes were
washed with 0.05% Tween-20 in Tris-Buffered saline (TBST) and incubated with
horseradish peroxidase (HRP)-conjugated goat anti-mouse and/or goat anti-rabbit IgG
(KPL Biomedical, Chantilly, VA). The enhanced chemi-luminescence (ECL) technique
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was used for the detection of protein bands. The intensities of protein bands were
measured using Labworks software (UVP Lab Products, Upland, CA).
4.2.3. Confocal microscopy
MDA-MB-231 and MCF7 cells were grown overnight in 4-well chambered Lab-TEK II
slides containing either DMEM/F12 media or RPMI-1640. The cells were treated with
AA and/or NDGA and were fixed with methanol (100%, chilled) for 5 min at -20 oC
before blocking with normal goat serum (NGS, 5%; Sigma) for 1 h. Methanol-fixed cells
were incubated overnight in the cold room with anti-caveolin-1 antibody (1:200;
polyclonal, Santa Cruz Biotechnology) or anti-CTXB antibody (1:200; monoclonal, Gibco
Invitrogen, Carlsbad, CA) in 1% NGS. The slides were washed three times and
incubated with fluorescein isothiocyanate (FITC)-conjugated goat anti-rabbit or antimouse antibody, mounted with ProLong® Gold antifade reagent mixed with DAPI
(Gibco Invitrogen). The confocal images were captured with the help of an LSM 700
Zeiss confocal microscope and analyzed using Zen 2009 software (Carl Zeiss,
Thornwood, NY). Each experiment was repeated three times, then cells were randomly
selected from each slide, and the same resolution, laser power, and detector-gain were
used. The student’s t tests were used to assess differences (means) between the
treatment and control. P < 0.05 was considered significant.
4.2.4. Cholesterol assay
Cellular cholesterol content was quantitated using Amplex Red Cholesterol assay kit
(Gibco Invitrogen) according to the manufacturer’s instructions. Briefly, cells (~1x105

92

cells/well) were placed in 12-well plates, incubated for 24 h, and treated as mentioned
previously. Cell lysates were prepared from each well, and equal concentrations of
proteins were used for this flourescence-based assay. The samples were measured
with a fluorescence microplate reader (Bio-Rad, Hercules, CA) using excitation of 530
nm and emission of 590 nm.

4.2.5. Migration and invasion assay
Cells were plated at a density of ~0.5 x 106 in each well of a 6-well plate in the presence
of media (RPMI-1640 or DMEM) containing 5% serum for 24 h. The monolayers were
wounded by scratching with a 10-L pipette tip. Images were captured using a Nikon
TMS microscope equipped with a Nikon F-601 camera. Cells that had migrated
between wounded regions were counted at three different observations (n = 3), and cellinvasion assays were carried out in Transwell chambers. Briefly, cells were cultured in
12-well plates (~3 x 105/well) for 24 h in the presence of MBCD as described above.
Cells were harvested, suspended in 500 l of medium containing 5% FBS, and added to
the upper layer of Transwell chambers. The bottom wells were filled with 1 ml of culture
medium containing 10% FBS (to promote cell growth and invasion through the matrigel
of Transwell chambers). The cells that were migrated to the lower chamber after 24 h of
incubation were examined and photographed by a Nikon TMS microscope equipped
with a Nikon F-601 camera. Migrated cells were also stained with calcein (Invitrogen,
Carlsbad, CA), a fluorescent dye that labels the viable cells. Both cell counts and
fluorescence intensities were taken into account to measure the invasiveness.
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4.3. RESULTS
4.3.1. Arachidonic acid-induced LR/caveolae syntheses
LTB4 or other cysteinyl-LTs synthesized from AA by LOX pathways are secreted from
the cells and act via G-protein-coupled BLT receptors. It has been postulated that BLT
receptors (i.e., BLT-1 and BLT-2) are located within the LRs of human neutrophils and
that disruption of LRs suppresses LTB4 syntheses [60]. Because AA-stimulated LTB4
production in MDA-MB-231 cells and LTB4 was found to be associated with cell
migration and invasion, we asked whether if LTB4-mediated cell movement occurs
through the LRs/caveolae.
First, LRs in both MDA-MB-231 and MCF7 cells were identified by labeling with anticaveolin-1 antibody (Figure 19C) and an Alexa flour-conjugated cholera toxin subunit B
(CTXB) LR labeling kit (Figure 20). Our initial investigation indicated that MDA-MB-231
and MCF7 cells react differently to anti-caveolin-1 antibody and CTX B labeling reagent.
We noted that MDA-MB-231 cells, while they could be labeled with anti-caveolin-1
antibody (Figure 19C), showed little or no reactivity with CTX B labeling reagent (Figure
20). On the other hand, MCF7 reacted with CTXB (Figure 20) but not with anti-caveolin
antibody (Figure 19C), suggesting that caveolae (a subset of LRs) are more
predominant in MDA-MB-231 cells than MCF7. We found that AA treatment increased
the anti-caveolin-1 antibody labeling of MDA-MB-231 cells by ~2-fold (Figure 19D) and
that NDGA blocked the labeling significantly (photographs a–d, Figures 19C and 19D).
The expression of caveolin-1 protein (an important marker of caveolae) by MDA-MB231 is shown in Figure 19A. As expected, MCF7 cells did not demonstrate any caveolin1 protein expression (data not shown). While AA increased the expression of caveolin-1
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protein, NDGA inhibited its expression (Figure 19A). The densitometric analyses of
Figure 2A are illustrated in Figure 2B. Flotilin-1, another important determinant of LR
composition, showed a high level of expression in MDA-MB-231 cells, which increased
further (~2-fold) by AA treatment. In contrast, MCF7 cells exhibited low Flotilin-1
expression, which was increased ~3-fold by AA treatment (Figure 21).
Because cholesterol is an important component of the LR and caveolae, and because
AA stimulated the caveolae expression as judged by labeling with anti-caveolin antibody
followed by confocal microscopy, we measured the cholesterol level in MDA-MB-231
and MCF7 cells to explore whether cholesterol synthesis is also affected by AA
treatment. Total cellular cholesterol was measured with the help of a commercially
available Amplex Red assay kit following the strategy described in the Materials and
Methods section. The results demonstrate (Figure 22) that the cholesterol level in MDAMB-231 cells is slightly higher than MCF7 and is stimulated by AA treatment (~0.4-fold).
AA-induced excess cholesterol synthesis was inhibited by NDGA and by methyl-cyclodextrin (MBCD), a common LR disruptor (Figure 22).
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Figure 19
Arachidonic acid induces the caveolin-1 expression in MDA-MB-231 cells
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C

D

Figure 19

97

Figure 19. Arachidonic acid induces the caveolin-1 expression in MDA-MB-231
cells
MDA-MB-231 and MCF7 cells were grown in 6-well plates or 4-well chambered slides
and treated with AA (100 M), AA (100 M) +NDGA (10 M), or NDGA (10 M) for 24 h
and subjected to immunoblot and immunoconfocal microscopy. Fig. 19A represents the
synthesis of caveolae as determined by labeling with anti-caveolin-1antibody.
Photograph a: MDA-MB-231, control; photograph b: treatment with AA (100 M);
photograph c: AA (100 M) +NDGA (10 M) treatment; photograph d: NDGA (10 M)
treatment. Arrow denotes membrane, and asterisk indicates the nucleus. Bar: 10 M.
The fluorescence intensities of control and treated cells were measured by Zeiss ZEN
confocal software and are shown in Fig. 19B. The expressions of caveolin-1 in control
and treated cells are shown in Fig. 19C. Figure 19D represents the densitometric
analyses of caveolin expression. All experiments were repeated at least three times,
and the data are given as means ± SE, * p < 0.001.
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Figure 20
Labeling of MDA-MB-231 and MCF7 cells with anti-cholera toxin antibody
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Figure 20. Labeling of MDA-MB-231 and MCF7 cells with anti-cholera toxin
antibody
MDA-MB-231 (Figure 20A) and MCF7 (Figure 20B) cells were grown in 4-well chamber
slides (LABTEK II) and then treated with AA and /or NDGA as mentioned previously.
The cells were fixed and labeled with anti-Ctx-B antibody (FITC-conjugated) to detect
mono-sialo ganglioside (GM1) located in the lipid rafts. Nucleus was stained with the
DAPI. Photograph a: MDA-MB-231, control; photograph b: AA-treatment; photograph c:
treatment with AA+NDGA; photograph d: NDGA treatment; photograph e: MCF7control;
photograph f: AA treatment; photograph g: treatment with AA+NDGA, and photograph
h: the treatment with NDGA. Arrow denotes cell membrane and asterisk indicates the
nucleus. Bar: 10 M.
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Figure 21
Flotilin-1 expression in MDA-MB-231 and MCF7cells
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Figure 21. The expression of flotilin-1 in MDA-MB-231 and MCF7 cells
Control and arachidonic acid treated MDA-MB-231 and MCF7 cells were harvested,
lysed and analyzed by immunoblot analysis to detect the protein expression of flotilin-1.
GAPDH was used as a loading control.
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Figure 22
Assay of total cellular cholesterol
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Figure 22. Assay of total cellular cholesterol
Approximately 1 X 105 cells were grown in a 12-well plate for overnight and were treated
with AA (100 M), AA (100 M) +NDGA (10 M), NDGA or MBCD (methyl beta
cyclodextrin; a common lipid-raft inhibitor) for 24 h. The cell lysates were used to
analyze cholesterol levels using the Amplex Red cholesterol assay kit as mentioned in
the Materials and Methods section of this chapter. Data represent the average of three
different experiments. *p<0.01, ** p<0.001.
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4.3.2. Lipid rafts in MDA-MB-231 are linked to cellular migration and invasion

The migration and invasion assays were performed to examine whether blocking of the
caveolae synthesis interferes with the mobility of MDA-MB-231. As shown, MBCD
reduced cellular migration in MDA-MB-231 cells by ~2-fold (photograph b, Figure 23A).
Figure 23B shows the quantitative values of migration assay. Likewise, the invasion
assay demonstrated that MBCD reduced the number of migratory cells across the
matrigel by ~2- to 3-fold (Figure 24B and 24C), which further suggests that LTB4mediated invasion of MDA-MB-231 cells involves cholesterol-regulated caveolae
biosynthesis.

105

A

B

Figure 23
The inhibitor of lipid rafts blocks the migration of MDA-MB-231 cells
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Figure 23. The inhibitor of lipid rafts blocks the migration of MDA-MB-231 cells
Approximately 1 X 106 cells were grown in a 6-well plate in growth medium
supplemented with 5% FBS. The cells (~70–80% confluent monolayer) were scratchwounded by a 10-M pipette tip and were treated with 1mM MBCD. Figure 23A
demonstrates the effect of MBCD (1 mM) on the migration of MDA-MB-231
(photographs a and b) and MCF7 (photographs c and d) cells. Figure 23B is the
graphical representation of the results of migration experiments shown Figure 23A. The
experiments were repeated three times, and the data are given as means ± SE; *p <
0.01, ** p < 0.001.
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Figure 24
MBCD inhibits the invasion by MDA-MB-231 cells
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Figure 24. MBCD inhibits the invasion by MDA-MB-231 cells
Cells were cultured in a 12-well plate and were treated with MBCD (1mM) for 24 h. Cells
were harvested and resuspended in 500 l medium containing 5% serum and applied
on the upper wells of a Transwell chamber as mentioned before. The bottom wells were
filled with 1 ml of complete culture medium containing 10% serum. The photographs of
invading breast cancer cells in 24-h in the lower wells were captured (Figure 24A) and
counted from four different microscopic fields. Figure 24B represents the average
number of cells counted. The invaded cells in the lower wells were stained with 2M of
calcein and incubated for 30 min at room temperature. The fluorescence of the viable
cells was measured by fluorescence plate reader at an excitation and emission of 490
and 520. Figure 24C represents the mean fluorescence of the viable wells. The results
shown here are the average of two individual experiments which were carried out in
duplicate.
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4.4. CONCLUSION

Because LRs play critical roles in activating signal cascades in cancer cells [16], and
because LR is known to house BLT receptors [15], we thought it would be interesting to
investigate whether the proper assembly of LRs/caveolae is important for AA-induced
migration of cancer cells. This is important because we observed that LR/caveolae
syntheses in MDA-MB-231 cells is stimulated by AA, which could be due to the binding
of LTB4 with BLT receptor located in the membrane caveolae. Because cholesterol is
one of the major constituents of LRs and MBCD binds to cholesterol—resulting in
disruption of the LRs—I questioned whether LRs have any significant role in the cellular
migration and invasion. It was observed that the disruption of LR/caveolae by MBCD
interferes with the migration and invasion of MDA-MB-231 cells (Figures 23 and 24).
This observation further supports our hypothesis that the assembly and location of BLT
receptor within the caveolae are important for transducing LTB4-mediated signaling for
migration and invasion. As shown in Figure 3, AA also stimulates the GM1 labeling in
MCF7 cells, which could be due to the fact that AA is internalized via LRs and interacts
with various molecules and receptors other than BLTs to generate downstream
signaling for growth and malignancy.
Thus, the results described in this chapter provide new evidence that AA promotes
metastatic signaling in invasive breast cancer cells by activating 5-LOX-mediated
cytokine secretion and the formation of caveolae.

110

CHAPTER 5

DISCUSSION

OVERALL PERSPECTIVE, PROPOSED MODEL, AND FUTURE
DIRECTIONS.
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5.1. OVERALL PERSPECTIVE

Breast cancer is one of the major causes of cancer-related death in the United States.
The current treatments include endocrine therapies and targeted molecular therapies to
treat patients diagnosed with cancers in the breast tissues. However, in many
instances, patients develop drug-resistance (or even multi-drug-resistant) breast
cancers that could be the result of mutations of target molecules and/or receptors as
well as the over-expression of the ATP-binding cassette subfamily G member 2
(ABCG2) [135]. Therefore, it is imperative to take a new look at the strategy of target
identification and to develop new anti-cancer agents that are effective, that are low in
toxicity, and do not develop the MDR (multiple drug resistance) phenomenon.
Elucidating the signaling pathways associated with the tumor progression in different
subtypes of breast cancer is necessary to develop new therapeutics. As far as signaling
molecules and receptors are concerned, invasive breast cancers are often
characterized by activated receptor tyrosine kinase-mediated PI3K/Akt/mTOR or
Ras/MEK/MAPK signaling, both of which are associated with activation of oncogenes.
Understandably, in recent years the therapeutic strategies were developed using a
combination of small-molecule inhibitors against PI3K, mTOR, or MAPK (e.g.,
everolimus, BEZ235, etc.) along with anti-receptor (anti-HER2, anti-EGFR, etc.)
antibodies or hormonal analogues (e.g., tamoxifane, raloxifene, etc.) to treat the
incidence of invasive breast cancers. Carracedo et al. [136] showed MAPK activation as
a result of mTOR inhibition in breast cancer cells, which suggests that targeting any
single pathway in the cancer processes may not be an effective strategy to limit the
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tumorigenesis anymore. On the other hand, a large number of ER+ cancer patients
develop resistance against the most widely used breast cancer drug, tamoxifen, due to
the activation of the Akt molecule by epigenetic changes [137; 138] HER-2 positive
metastatic breast cancer patients are successfully treated with anti-HER-2 antibody and
trastuzumab, but a long-term use of trastuzumab leads to the drug resistance
tumorigenesis [139; 140]. To tackle this problem, new anti-cancer small-molecule
inhibitors have been designed and tested clinically. This group of drugs includes: (1)
tyrosine inhibitor or lapatinib [141], (2) PARP1 inhibitor or olaparib [142], (3) mTOR
inhibitor rapamycin and its analogues [41; 113], and (4) sheddase inhibitors [143].
mTORC1 and mTORC2 are also indicated as promising therapeutic candidates
because to their important roles in the activation of various oncogenes [144].
While the HER-2 and ER+ cancers are already having potential therapeutic targets, the
question arises as to what the target and strategy should be in the future for treating
patients with triple-negative breast cancers or TNBCs? Interestingly, recent reports
suggest that there are numerous possible therapeutic targets in TNBCs: serinethreonine protein kinase (Chk1) [145], HLA-DR antigens-associated invariant chain or
CD74 (CD74) [146], signal transducer and activator of transcription-1 (Stat 1) [146],
lysyl oxidase [147], etc. A detailed study by Lehmann et al. [6] reported that different
genetic subtypes such as BL1 and BL2 (cell-cycle- and cell-division-specific genes), IM
(genes connected with immune signal transduction), M and MSL (genes involved in cell
motility, cell differentiation, and ECM receptor interactions), and LAR (other hormoneregulated pathways such as Androgen receptor signaling), etc., could also be potential
targets for developing new therapies against TNBCs. Ueno et al. [148] mentioned the
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EGFR over-expression in TNBC and a successful inhibition of cell growth by using
erlotinib, an EGFR tyrosine kinase inhibitor, which could be another approach to
developing therapy against this highly metastatic breast cancer.
Inflammation-mediated signaling pathway and the transformation of normal cells to
malignancy has been long debated, but still very little is known about the association of
inflammatory molecules and their role in tumor formation. Over-expression of COX and
LOX and their metabolites has been shown to enhance carcinogen metabolism, tumorcell proliferation, and metastatic potential in colon, lung, and breast cancer patients,
which justifies the use of anti-COX or anti-LOX drugs for treatment. Although the
association between PUFA metabolism, COX/LOX over-expression, and the secretion
of inflammatory eicosanoids has been referred to in relation to different cancers, there is
still a knowledge gap about how the bioactive lipid mediators (i.e., the products of COX
and LOX pathways) interact with various signaling and inflammatory molecules and
promote malignancy in breast tissues. Incidentally, a recent report by Rokavec et al.
[149] on invasive breast cancers indicated an emerging role of inflammatory cytokine IL6, which suppresses the microRNA-200C (necessary for restricting the inflammation)
and triggers the MEK/MAPK and IKK/NFkB pathway for consistent signaling in
malignancy. IL-8, another major inflammatory cytokine, is a novel marker for tumor
aggressiveness in receptor-negative breast cancers [150]. Secretion of these cytokines
in the tumor micro-environment regulates the self-renewal pathways of cancer cells and
activates the pro-carcinogenic PI3K/Stat3/NFkB signaling [151].
In this dissertation, I observed that the invasive TNBC cells MDA-MB-231 respond to
AA very differently than do ER+-MCF-7 cells, which could be due to their geneotypic and
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phenotypic makeup and other intrinsic metabolic functions. The innovativeness of my
dissertation comes from the observation that LTB 4, a product of 5-LOX, is synthesized
under the influence of excess AA (100 M) and plays a significant role in activating
inflammatory molecules and determining the metastatic migration and invasion. This
could be considered an important paradigm shift from the previous concept that COX-2
and prostaglandins are the most important pathways involved in the development of
breast cancer [152]. While I am not in a position to refute the important role of COX-2, I
propose that the role of LOX pathway is equally important. In fact, the role of 5-LOX in
the formation of colonic polyps [84] and malignancy in breast cancer [97] supports the
findings in my research. Future research from our laboratory and laboratories around
the world should validate whether 5-LOX and related pathways could be considered as
novel targets for developing anti-breast-cancer drugs.

5. 2. PROPOSED MODEL

Based on my results, I have proposed a hypothetical model (Figure 26) describing the
overall pathway that leads to the migration and invasion of MDA-MB-231 cells. As
indicated, exogenous AA is internalized and incorporated into membrane phospholipids,
followed by release from the membrane by the action of cytoplasmic phospholipase-A2
(cPLA2) into the cytoplasm [54]. Free AA is then converted into LTB4 by activated 5-LOX
and is subsequently released from the cells. Secreted 5-LOX then activates the cell by
binding with BLT receptor (via autocrine and paracrine signaling) located in the
caveloae/LR. LTB4 subsequently stimulates the cells by activating the transcription
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factor NF [153] that up-regulates the expression of cytokine genes such as IL-6 and
IL-8. The increased production of these inflammatory cytokines is either directly or
indirectly linked to the migration and invasion by MDA-MB-231 cells. Earlier, AA was
reported to increase the migration of MDA-MB-231 cells by activating focal adhesion
kinase (FAK) [9], but the actual mechanism was not proposed. Thus, it is possible that
AA induces the migration of invasive breast cancer cells by activating FAK via LTB4 and
IL-6/IL-8 cytokines. Recently, Wen et al. [97] have reported that AA treatment enhances
the incidence of mammary cell tumorigenesis by activating LOX and m-TOR pathways,
further supporting the idea that LOX is equally important as COX-2 and should be
considered as a potential target for developing new chemotherapeutic agents to reduce
the incidence of breast cancer metastasis.

116

Figure 25
Proposed Model
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Figure 25. Integrated results proposing the arachidonic acid stimulated pathway
in MDA-MB-231 cells
The model proposes that exogenous AA is taken up by caveolae-mediated endocytic or
non-endocytic (simple diffusion or via fatty acid transporters) mechanisms and
incorporated into membrane phospholipids to produce AA-PL. AA-PL is then hydrolyzed
by cPLA2 and releases free AA that stimulates the activity of 5-LOX. Activated 5-LOX
converts AA to LTB4. The secreted LTB4 regulate the migration and invasion by a
mechanism yet to be elucidated. LTB4 which is secreted by the cell probably re-enters
via LR/caveolae and activates NF to produce phospho-NF. Phosphorylation of
NF upregulates the expression of IL-6 and IL-8 genes, which produce the
inflammatory reactions, migrations and invasions by MDA-MB-231 cells.
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5. 3. FUTURE DIRECTIONS

Currently, our laboratory is in the process in generating 5-LOX knockout and overexpressed MDA-MB-231 cells, which will be used to conduct an in-depth investigation of
the mechanism of cell invasion and malignancy in breast cancer. SiRNA-mediated
knocking down of 5-LOX in invasive breast cancer cells to determine whether the LOX
pathway is crucial for maintaining the cancerous properties should also be pursued.
Determining

the

possible

lamelopodia/invadopodia

link

formation

between

AA-induced

is another important

LTB4
area

production

and

needing to be

investigated. Cancer cells maintain their invasiveness by forming lamelopodia/
invadopodia using membrane-bound molecules located in the lipid rafts/caveolae.
Therefore, it would be interesting to determine if the proper assembly and disassembly
of lipid rafts are essential for LTB4-mediated activation of MDA-MB-231 cells.
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